A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.
The U.S. company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Oversubscribed, series B financing for Noema Pharma’s clinical stage assets has been successfully closed raising $112 million from new and existing investors.
